Human immunity and the design of multi-component, single target vaccines

PLoS ONE

Volumn 2, Issue 9, 2007, Pages

  Saul, Allan ^a   Fay, Michael P ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; STAPHYLOCOCCUS VACCINE; TETANUS TOXOID; VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DATA BASE; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MATHEMATICAL MODEL; PREDICTION; IMMUNOLOGY; SYNTHESIS; THEORETICAL MODEL;

DRUG DESIGN; HUMANS; MODELS, THEORETICAL; VACCINES;

EID: 41049112878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000850     Document Type: Article

References (29)

1. Bagnoli F, Rappuoli R (2006) Targeting infectious diseases in the genomics era. Curr Opin Investig Drugs 7: 695-698.
2. Goto Y, Coler RN, Reed SG (2007) Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun 75: 846-851.
3. Wu Y, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, et al. (2006) Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex, Proc Natl Acad Sci U S A 103: 18243-18248.
4. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, et al. (2007) Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 104: 293-298.
5. Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7: 179-190.
6. Miller LH, Saul A, Mahanty S (2005) Revisiting Freund's incomplete adjuvant for vaccines in the developing world. Trends Parasitol 21: 412-414.
7. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350: 1569-1577.
8. Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, et al. (2005) The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis 191: 81-88.
9. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179: 489-492.
10. Siber GR (1997) Methods for estimating serological correlates of protection. Dev Biol Stand 89: 283-296.
11. Taranger J, Trollfors B, Lagergard T, Sundh V, Bryla DA, et al. (2000) Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181: 1010-1013.
12. Sturgess AW, Rush K, Charbonneau RJ, Lee JI, West DJ, et al. (1999) Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 17: 1169-1178.
13. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
14. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
15. Kumar S, Epstein JE, Richie TL, Nkrumah FK, Soisson L, et al. (2002) A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol 18: 129-135.
16. Li S, Locke E, Bruder J, Clarke D, Doolan DL, et al. (2007) Viral vectors for malaria vaccine development. Vaccine 25: 2567-2574.
17. Dickman S (2003) Tough mining: the challenges of searching the scientific literature. PLoS Biol 1: E48.
18. Reed GF, Meade BD, Steinhoff MC (1995) The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 96: 600-603.
19. Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52: 591-611.
20. Greco WR, Brave G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385.
21. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26: 585-615.
22. Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 440: iv-vii.
23. Burgess MA, Rodger AJ, Waite SA, Collard F (2001) Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine 19: 4835-4841.
24. Dagan R, Goldblatt D, Maleckar JR, Yaich M, Eskola J (2004) Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72: 5393-5391.
25. Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, et al. (2006) Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine 24: 2043-2048.
26. Vandepapeliere P, Rehermann B, Koutsoukos M, Moris P, Carcon N, et al. (2005) Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B Antigens using AS02A adjuvant in healthy adults. Vaccine 23: 2591-2601.
27. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, et al. (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodcoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immumol 24: 693-701.
28. Goldenthal KL, Falk LA, Ball L, Geber A (2001) Prelicensure evaluation of combination vaccines. Clin Infect Dis 33 Suppl 4: S267-S273.
29. Anon (1997) Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. Rockville, MD.: US Food and Drug Administration, Center for Biological Evaluation and Research.